Bridgette Heller Sells 1,012 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) Director Bridgette Heller sold 1,012 shares of DexCom stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total transaction of $60,730.12. Following the completion of the transaction, the director directly owned 25,007 shares of the company’s stock, valued at $1,500,670.07. This trade represents a 3.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Up 6.6%

Shares of DexCom stock opened at $61.63 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The stock has a market capitalization of $23.78 billion, a PE ratio of 26.34, a price-to-earnings-growth ratio of 1.00 and a beta of 1.40. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The company has a 50-day simple moving average of $63.46 and a two-hundred day simple moving average of $65.89.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.09. The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.32 earnings per share. On average, analysts anticipate that DexCom, Inc. will post 2.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several research reports. Citigroup reissued a “buy” rating and set a $79.00 price objective (down from $84.00) on shares of DexCom in a report on Monday, May 4th. BTIG Research reissued a “buy” rating and set a $85.00 price objective on shares of DexCom in a report on Monday, March 9th. Wells Fargo & Company decreased their price objective on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a report on Friday, February 13th. Robert W. Baird set a $80.00 price objective on shares of DexCom in a report on Friday, May 1st. Finally, Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $83.22.

Institutional Trading of DexCom

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Trust Co. of Vermont increased its holdings in DexCom by 14.8% during the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after buying an additional 145 shares during the last quarter. CVA Family Office LLC boosted its position in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the period. V Square Quantitative Management LLC boosted its position in shares of DexCom by 1.8% in the first quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock worth $604,000 after purchasing an additional 172 shares during the period. Essex Financial Services Inc. boosted its position in shares of DexCom by 5.7% in the first quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock worth $204,000 after purchasing an additional 175 shares during the period. Finally, IFP Advisors Inc boosted its position in shares of DexCom by 24.7% in the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after purchasing an additional 178 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Key DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom outlined a 2030 growth plan calling for at least 10% annual revenue growth through 2030, along with margin targets that suggest improving profitability over time. Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
• Positive Sentiment: The company authorized a new $1 billion share buyback, which can support the stock by signaling confidence in future cash flow and returning capital to shareholders. Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
• Positive Sentiment: Management also highlighted next-generation products, including the G8 glucose sensor and dual-analyte sensing, which could expand DexCom’s competitive position and addressable market. Dexcom to add 2 board directors with activist investor Elliott
• Positive Sentiment: DexCom and Elliott Investment Management agreed to add two independent directors to the board and revise governance, a move that may improve oversight and strategic execution. Dexcom to appoint two directors, revamp board committee with Elliott
• Neutral Sentiment: Wall Street sentiment remains constructive overall, with a “Moderate Buy” consensus and an average price target above recent trading levels, though there are still some hold and underweight ratings in the mix. Are Wall Street analysts bullish on DexCom’s stock?
• Negative Sentiment: Director Bridgette Heller sold 1,012 shares, but the transaction was small and was made under a pre-arranged trading plan, so it is less likely to be a major negative signal. Bridgette Heller Sells 1,012 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.